dc.contributor.author
Schöpe, Paul Curtis
dc.contributor.author
Zinnow, Viktoria
dc.contributor.author
Ishfaq, Muhammad Ahtisham
dc.contributor.author
Smith, Janice
dc.contributor.author
Herrmann, Pia
dc.contributor.author
Shoemaker, Robert H.
dc.contributor.author
Walther, Wolfgang
dc.contributor.author
Stein, Ulrike
dc.date.accessioned
2023-09-22T14:43:38Z
dc.date.available
2023-09-22T14:43:38Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/40953
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-40674
dc.description.abstract
Colorectal cancer (CRC) is the third most prevalent and second deadliest cancer worldwide. In addition, metastasis directly causes up to 90% of all CRC deaths, highlighting the metastatic burden of the disease. Biomarkers such as S100A4 and MACC1 aid in identifying patients with a high risk of metastasis formation. High expression of S100A4 or MACC1 and to a greater extent the combination of both biomarkers is a predictor for metastasis and poor patient survival in CRC. MACC1 is a tumor-initiating and metastasis-promoting oncogene, whereas S100A4 has not been shown to initiate tumor formation but can, nevertheless, promote malignant tumor growth and metastasis formation. Cantharidin is a natural drug extracted from various blister beetle species, and its demethylated analogue norcantharidin has been shown in several studies to have an anti-cancer and anti-metastatic effect in different cancer entities such as CRC, breast cancer, and lung cancer. The impact of the natural compound cantharidin and norcantharidin on S100A4 and MACC1 gene expression, cancer cell migration, motility, and colony formation in vitro was tested. Here, for the first time, we have demonstrated that cantharidin and norcantharidin are transcriptional inhibitors of S100A4 and MACC1 mRNA expression, protein expression, and motility in CRC cells. Our results clearly indicate that cantharidin and, to a lesser extent, its analogue norcantharidin are promising compounds for efficient anti-metastatic therapy targeting the metastasis-inducing genes S100A4 and MACC1 for personalized medicine for cancer patients.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
colorectal cancer
en
dc.subject
norcantharidin
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Cantharidin and Its Analogue Norcantharidin Inhibit Metastasis—Inducing Genes S100A4 and MACC1
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
1179
dcterms.bibliographicCitation.doi
10.3390/ijms24021179
dcterms.bibliographicCitation.journaltitle
International Journal of Molecular Sciences
dcterms.bibliographicCitation.number
2
dcterms.bibliographicCitation.originalpublishername
MDPI
dcterms.bibliographicCitation.volume
24
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
36674695
dcterms.isPartOf.eissn
1422-0067